Latest News
Category: Clinical
Telix welcomes the Society of Nuclear Medicine and Molecular Imaging (SNMMI) updated Appropriate Use Criteria (AUC) for prostate specific membrane antigen (PSMA) positron emission tomography (PET)...
Read more
Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes PSMA PET imaging modalities, including Ga-68...
Read more
Telix announces the FDA has accepted the IND Application to undertake a clinical study of Telix’s investigational kidney cancer therapy,...
Read more
Telix has completed a Phase I clinical trial of TLX591-CDx for prostate cancer imaging in Japan in collaboration with Kanazawa...
Read more
Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI® in radioguided surgery...
Read more
Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt,...
Read more
Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx in breast...
Read more
Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being investigated in lung and ovarian...
Read more
Telix announces Phase II academic study of TLX66 in children with high-risk...
Read more
Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study of TLX592 in patients with advanced prostate...
Read more